Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > PEAR Pear Therapeutics > Detailed Quotes

PEAR Pear Therapeutics

Watchlist
1.090
+0.010+0.93%
Close  01/31 16:00 ET
1.120
+0.030+2.75%
Post Mkt Price 01/31 19:34 ET
High
1.150
Open
1.100
Turnover
150.06K
Low
1.080
Pre Close
1.080
Volume
136.21K
Market Cap
152.63M
P/E(TTM)
Loss
52wk High
6.740
Shares
140.03M
P/E(Static)
Loss
52wk Low
0.981
Float Cap
40.30M
Bid/Ask %
77.78%
Historical High
14.600
Shs Float
36.98M
Volume Ratio
0.63
Historical Low
0.000
Dividend TTM
--
Div Yield TTM
--
P/B
2.92
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.37%
Amplitude
6.48%
Avg Price
1.101
Lot Size
1
Float Cap
40.30M
Bid/Ask %
77.78%
Historical High
14.600
Shs Float
36.98M
Volume Ratio
0.63
Historical Low
0.000
Dividend TTM
--
P/B
2.92
Dividend LFY
--
Turnover Ratio
0.37%
Amplitude
6.48%
Avg Price
1.101
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Pear Therapeutics, Inc.( formerly Thimble Point Acquisition Corp. ) is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA.
CEO: Dr. Corey McCann, Pd.D
Market: NASDAQ
Listing Date: 02/02/2021
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist